Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis
Primary melanoma aggressiveness is determined by rapid selection and growth of cellular clones resistant to conventional treatments, resulting in metastasis and recurrence. In addition, a reprogrammed tumor-immune microenvironment supports melanoma progression and response to therapy. There is an ur...
Main Authors: | Giorgiana Negrea, Valentin-Florian Rauca, Marta Szilvia Meszaros, Laura Patras, Lavinia Luput, Emilia Licarete, Vlad-Alexandru Toma, Alina Porfire, Dana Muntean, Alina Sesarman, Manuela Banciu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.870347/full |
Similar Items
-
Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment
by: Emilia Licarete, et al.
Published: (2020-04-01) -
A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy
by: Cristina Ioana Barbălată, et al.
Published: (2021-09-01) -
An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer
by: Iulia Rus, et al.
Published: (2021-01-01) -
Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity
by: Michela Pecoraro, et al.
Published: (2023-04-01) -
Bacteriostatic effect of simvastatin on selected oral streptococci in vitro
by: Eugene J Whitaker, et al.
Published: (2017-01-01)